The China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has accepted BeiGene’s supplemental biologics license application (sBLA) for tislelizumab to treat hepatocellular carcinoma (HCC).
The US Food and Drug Administration (FDA) has accepted for review of Pfizer’s biologics license application (BLA) for its investigational pentavalent meningococcal vaccine candidate, MenABCWY.
The US Food and Drug Administration (FDA) has approved Acer Therapeutics’ olpruva (sodium phenylbutyrate) to treat patients with urea cycle disorders (UCDs).
The Japanese Ministry of Health, Labor, and Welfare (MHLW) has granted marketing authorisation for MediWound’s NexoBrid to remove nonviable burn tissue, or eschar.
Boehringer Ingelheim has received conditional marketing authorisation from the European Commission (EC) for its new humanised selective antibody, spesolimab, to treat adult patients with generalised pustular psoriasis (GPP) flares.
Health Canada has granted approval for VBI Vaccines’ PreHevbrio [3-antigen Hepatitis B Vaccine (Recombinant)] to prevent Hepatitis B virus (HBV) in adults.
The US Food and Drug Administration (FDA) has granted fast track designation for IDEAYA Biosciences’ development programme studying darovasertib in combination with crizotinib to treat metastatic uveal melanoma (MUM).
The European Medicines Agency (EMA) has validated GSK’s marketing authorization application (MAA) for momelotinib to treat myelofibrosis.
Aldeyra Therapeutics has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for topical ocular reproxalap, to treat signs and symptoms of dry eye disease.
The US Food and Drug Administration (FDA) has granted fast track designation (FTD) for Kintara Therapeutics’ late-stage photodynamic therapy (PDT), REM-001, to treat cutaneous metastatic breast cancer (CMBC).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.